ALK expands strategic partnership with Catalent for tablet production, committing approximately DKK 500 million for capacity expansion over three years.
Oct 01, 2026
Capital Region Of DenmarkBiotechnologyHealth Care
Description
ALK has announced an expanded agreement with Catalent for contract production, ensuring long-term access to Catalent's Zydis® technology. The extended partnership aims to enhance ALK's tablet production capacity significantly. The total payments to Catalent will be around DKK 500 million, activated over three years. This capacity expansion is crucial for meeting the future demand for ALK's SLIT-tablet portfolio.
Company Information
Company
ALK
Location
Capital Region Of Denmark, Denmark
About
ALK is a global, research-driven pharmaceutical company that focuses on the prevention, diagnosis, and treatment of allergies. It markets allergy immunotherapy treatments and other products and services for people with allergies and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,600 people worldwide.